Efficacy and safety of the indirect anticoagulant warfarin in its dosage based on the results of pharmacogenetic testing

Abstract

Abstract. Thrombotic complications are one of the main causes of death and disability, causing enormous economic damage to the state. There is an increase in the number of patients at high risk of these complications. The main aim of the article is to investigate efficacy and safety of the indirect anticoagulant warfarin in its dosage based on the results of pharmacogenetic testing.  To achieve that aim, the use of drugs (JIC) from the group of indirect oral anticoagulants (ACND) is the only and uncontested method of long-term outpatient prevention of thrombosis - their effectiveness has been proven in primary and secondary prevention of thromboembolic complications in patients with atrial fibrillation and, above all, ischemic stroke. AKND therapy reduces the risk of all strokes by an average of 62%. The advantage of AKND therapy has been proven in terms of preventing primary and recurrent thromboembolism.